Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zaoshi Huatan Xiefei is a Traditional Chinese Medicine (TCM) granule formulation developed for the treatment of severe community-acquired pneumonia (CAP). It is specifically indicated for patients presenting with the "pulmonary stagnation of phlegm" syndrome. The drug is intended to be used in an integrated medicine framework, combined with standard Western antibiotic therapy. Its pharmacological actions, according to TCM principles, involve resolving dampness, transforming phlegm, and draining the lungs to relieve obstruction and improve respiratory function. Clinical evaluation, including Phase 3 trials led by Henan University of Traditional Chinese Medicine, has focused on its efficacy in reducing clinical symptoms and improving recovery rates in hospitalized adults with severe CAP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zaoshi Huatan Xiefei granule.